Crystal structures of the M1 and M4 muscarinic acetylcholine receptors

Nature

Volumn 531, Issue 7594, 2016, Pages 335-340

  Thal, David M ^a   Sun, Bingfa ^b   Feng, Dan ^b   Nawaratne, Vindhya ^a   Leach, Katie ^a   Felder, Christian C ^c   Bures, Mark G ^c   Evans, David A ^c   Weis, William I ^d   Bachhawat, Priti ^b   Kobilka, Tong Sun ^b   Sexton, Patrick M ^a   Kobilka, Brian K ^b,d   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b ConfometRx ^*  (United States)

^c ELI LILLY AND COMPANY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; TIOTROPIUM BROMIDE; 3-AMINO-5-CHLORO-6-METHOXY-4-METHYL-THIENO(2,3-B)PYRIDINE-2-CARBOXYLIC ACID CYCLOPROPYLAMIDE; NICOTINIC ACID DERIVATIVE; THIOPHENE DERIVATIVE;

CRYSTAL STRUCTURE; DISEASE TREATMENT; DRUG; GENE; HORMONE; NERVOUS SYSTEM; NERVOUS SYSTEM DISORDER; RESEARCH WORK;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SELECTIVITY; HUMAN; PRIORITY JOURNAL; SURFACE PROPERTY; ALLOSTERIC SITE; ALLOSTERISM; ALZHEIMER DISEASE; CHEMISTRY; COMPARATIVE STUDY; CRYSTALLIZATION; DRUG EFFECTS; ENZYME SPECIFICITY; INVERSE AGONISM; METABOLISM; MOLECULAR MODEL; SCHIZOPHRENIA; STATIC ELECTRICITY; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINE; ALLOSTERIC REGULATION; ALLOSTERIC SITE; ALZHEIMER DISEASE; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG INVERSE AGONISM; HUMANS; MODELS, MOLECULAR; NICOTINIC ACIDS; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; SCHIZOPHRENIA; STATIC ELECTRICITY; SUBSTRATE SPECIFICITY; SURFACE PROPERTIES; THIOPHENES; TIOTROPIUM BROMIDE;

EID: 84982308386     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17188     Document Type: Article

References (65)

1. Wess, J., Eglen, R. M., & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature Rev. Drug Discov. 6, 721-733 (2007
2. Hasselmo, M. E. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol. 16, 710-715 (2006
3. Hasselmo, M. E., & Giocomo, L. M. Cholinergic modulation of cortical function. J. Mol. Neurosci. 30, 133-135 (2006
4. Kruse, A. C., et al. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nature Rev. Drug Discov. 13, 549-560 (2014
5. Kruse, A. C., Hu, J., Kobilka, B. K., & Wess, J. Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development. Curr. Opin. Pharmacol. 16, 24-30 (2014
6. Foster, D. J., Jones, C. K., & Conn, P. J. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Discov. Med. 14, 413-420 (2012
7. Shekhar, A., et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165, 1033-1039 (2008
8. Bodick, N. C., et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54, 465-473 (1997
9. Heinrich, J. N., et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur. J. Pharmacol. 605, 53-56 (2009
10. Conn, P. J., Christopoulos, A., & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discov. 8, 41-54 (2009
11. Digby, G. J., Shirey, J. K., & Conn, P. J. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol. Biosyst. 6, 1345-1354 (2010
12. Keov, P., Sexton, P. M., & Christopoulos, A. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60, 24-35 (2011
13. Suratman, S., et al. Impact of species variability and ?probe-dependence? on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br. J. Pharmacol. 162, 1659-1670 (2011
14. Leach, K., et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35, 855-869 (2010
15. Chan, W. Y., et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl Acad. Sci. USA 105, 10978-10983 (2008
16. Shirey, J. K., et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J. Neurosci. 29, 14271-14286 (2009
17. Ma, L., et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl Acad. Sci. USA 106, 15950-15955 (2009
18. Abdul-Ridha, A., et al. Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor. J. Biol. Chem. 289, 6067-6079 (2014
19. Abdul-Ridha, A., et al. Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor. J. Biol. Chem. 289, 33701-33711 (2014
20. Leach, K., Davey, A. E., Felder, C. C., Sexton, P. M., & Christopoulos, A. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. Mol. Pharmacol. 79, 855-865 (2011
21. Nawaratne, V., Leach, K., Felder, C. C., Sexton, P. M., & Christopoulos, A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J. Biol. Chem. 285, 19012-19021 (2010
22. Kruse, A. C., et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552-556 (2012
23. Haga, K., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551 (2012
24. Caffrey, M., & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009
25. Chun, E., et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967-976 (2012
26. Thorsen, T. S., Matt, R., Weis, W. I., & Kobilka, B. K. Modified T4 lysozyme fusion proteins facilitate G protein-coupled receptor crystallogenesis. Structure 22, 1657-1664 (2014
27. van Rhee, A. M., & Jacobson, K. A. Molecular architecture of G protein-coupled receptors. Drug Dev. Res. 37, 1-38 (1996
28. Lu, Z.-L., Saldanha, J. W., & Hulme, E. C. Transmembrane domains 4 and 7 of the M1 muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch. J. Biol. Chem. 276, 34098-34104 (2001
29. Caulfield, M. P., & Birdsall, N. J. M. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50, 279-290 (1998
30. Goodwin, J. A., Hulme, E. C., Langmead, C. J., & Tehan, B. G. Roof and floor of the muscarinic binding pocket: variations in the binding modes of orthosteric ligands. Mol. Pharmacol. 72, 1484-1496 (2007
31. Gregory, K. J., Sexton, P. M., & Christopoulos, A. Allosteric modulation of muscarinic acetylcholine receptors. Curr. Neuropharmacol. 5, 157-167 (2007
32. Stockton, J. M., Birdsall, N. J., Burgen, A. S., & Hulme, E. C. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 23, 551-557 (1983
33. Gnagey, A. L., Seidenberg, M., & Ellis, J. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol. Pharmacol. 56, 1245-1253 (1999
34. Tautermann, C. S., et al. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. J. Med. Chem. 56, 8746-8756 (2013
35. Kruse, A. C., et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101-106 (2013
36. Conn, P. J., Jones, C. K., & Lindsley, C. W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30, 148-155 (2009
37. Schober, D. A., Croy, C. H., Xiao, H., Christopoulos, A., & Felder, C. C. Development of a radioligand, [3H]LY2119620, to probe the human M2 and M4 muscarinic receptor allosteric binding sites. Mol. Pharmacol. 86, 116-123 (2014
38. Croy, C. H., et al. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M2 and M4 receptors. Mol. Pharmacol. 86, 106-115 (2014
39. Khoury, E., Clément, S., & Laporte, S. A. Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics. Front. Endocrinol. 5, 68 (2014
40. Scarselli, M., Li, B., Kim, S. K., & Wess, J. Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation. J. Biol. Chem. 282, 7385-7396 (2007
41. Avlani, V. A., et al. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J. Biol. Chem. 282, 25677-25686 (2007
42. Lockless, S. W., & Ranganathan, R. Evolutionarily conserved pathways of energetic connectivity in protein families. Science 286, 295-299 (1999
43. Dolinsky, T. J., Nielsen, J. E., McCammon, J. A., & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665-W667 (2004
44. Dolinsky, T. J., et al. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res. 35, W522-W525 (2007
45. Baker, N. A., Sept, D., Joseph, S., Holst, M. J., & McCammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl Acad. Sci. USA 98, 10037-10041 (2001
46. McCoy, A. J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007
47. Skubák, P., Murshudov, G. N., & Pannu, N. S. Direct incorporation of experimental phase information in model refinement. Acta Crystallogr. D 60, 2196-2201 (2004
48. Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010
49. Adams, P. D., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213-221 (2010
50. Chen, V. B., et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010
51. Schrodinger, L. The PyMOL Molecular Graphics System, version 1.7.0.3 (2010
52. Schrödinger release 2014-2: Maestro, version 9.7 (2014
53. Guex, N., Peitsch, M. C., & Schwede, T. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. Electrophoresis 30 (Suppl. 1), S162-S173 (2009
54. Arnold, K., Bordoli, L., Kopp, J., & Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006
55. Grosdidier, A., Zoete, V., & Michielin, O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 39, W270-W277 (2011
56. Nawaratne, V., et al. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 74, 1119-1131 (2008
57. Motulsky, H., & Christopoulos, A. Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting (Oxford Univ. Press, 2004
58. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187-194 (1988
59. Celniker, G., et al. ConSurf: using evolutionary data to raise testable hypotheses about protein function. Isr. J. Chem. 53, 199-206 (2013
60. Ashkenazy, H., Erez, E., Martz, E., Pupko, T., & Ben-Tal, N. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 38, W529-W533 (2010
61. Landau, M., et al. ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucleic Acids Res. 33, W299-W302 (2005
62. Glaser, F., et al. ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 19, 163-164 (2003
63. Larkin, M. A., et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948 (2007
64. Molecular Operating Environment (MOE) (Chemical Computing Group, 2015
65. Karplus, P. A., & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030-1033 (2012